These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9772065)

  • 1. Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.
    Mann DE; Kessel ER; Mullins DL; Lottenberg R
    Am J Gastroenterol; 1998 Oct; 93(10):1960-2. PubMed ID: 9772065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
    Saif MW; Volpe BT; Dailey M; Tsongalis GJ
    Conn Med; 1997 Jun; 61(6):333-7. PubMed ID: 9238827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
    Jespersen J
    Eur J Contracept Reprod Health Care; 1996; 1(1):3-11. PubMed ID: 9678132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity to activated protein C; influence of oral contraceptives and sex.
    Henkens CM; Bom VJ; Seinen AJ; van der Meer J
    Thromb Haemost; 1995 Mar; 73(3):402-4. PubMed ID: 7667823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
    Endrikat J; Noah M; Gerlinger C; Bannemerschult R; Junge W; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Oct; 64(4):217-22. PubMed ID: 11747870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to activated protein C: a major cause of inherited thrombophilia.
    Jensen R; Ens GE
    Clin Lab Sci; 1997; 10(4):219-22. PubMed ID: 10169621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
    Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I
    Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired APC resistance and oral contraceptives: differences between two functional tests.
    Curvers J; Thomassen MC; Nicolaes GA; Van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Br J Haematol; 1999 Apr; 105(1):88-94. PubMed ID: 10233368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombophilia caused by congenital disorders of blood coagulation].
    Hiller E; Pihusch R
    Fortschr Med; 1998 Oct; 116(29):26-8, 30, 32 passim. PubMed ID: 9846471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
    Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC
    Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
    El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
    Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of activated protein C resistance among normal pregnancies of Hispanic women.
    Fassett MJ; Bohn YC; Kuo J; Wing DA
    Am J Obstet Gynecol; 2000 Jun; 182(6):1433-6. PubMed ID: 10871461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
    Fábregues F; Tàssies D; Reverter JC; Carmona F; Ordinas A; Balasch J
    Fertil Steril; 2004 Apr; 81(4):989-95. PubMed ID: 15066453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.